(Q43544436)

24 November 2017

title

Cost efficacy of tazobactam/piperacillin versus imipenem/cilastatin in the treatment of intra-abdominal infection (English)

1 reference

24 November 2017

1 reference

E S Dietrich

1

1 reference

24 November 2017

B Schubert

series ordinal

2

1 reference

24 November 2017

W Ebner

series ordinal

3

1 reference

24 November 2017

F Daschner

series ordinal

4

1 reference

24 November 2017

publication date

1 January 2001

1 reference

24 November 2017

1 reference

24 November 2017

volume

19

1 reference

24 November 2017

issue

1

1 reference

24 November 2017

page(s)

79-94

1 reference

Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections

24 November 2017

cites work

1 reference

12 December 2020

Intraabdominal infections: an overview.

1 reference

12 December 2020

Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections

1 reference

12 December 2020

Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: report from a Swedish Study Group.

1 reference

12 December 2020

Carbapenems: monotherapy in intra-abdominal sepsis

1 reference

12 December 2020

A comparison of imipenem/cilastatin with the combination of cefuroxime and metronidazole in the treatment of intra-abdominal infections

1 reference

12 December 2020

Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis

1 reference

12 December 2020

A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group.

1 reference

12 December 2020

Pharmacoeconomics of piperacillin/tazobactam and imipenem/cilastatin in the treatment of patients with intra-abdominal infections

1 reference

12 December 2020

The safety profile of imipenem/cilastatin: worldwide clinical experience based on 3470 patients

1 reference

12 December 2020

Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination.

1 reference

12 December 2020

Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial

1 reference

12 December 2020

Comparison of imipenem/cilastatin with the combination of aztreonam and clindamycin in the treatment of intra-abdominal infections.

1 reference

12 December 2020

The practice of meta-analysis

1 reference

12 December 2020

Management of intra-abdominal infections. The case for intraoperative cultures and comprehensive broad-spectrum antibiotic coverage. The Canadian Intra-abdominal Infection Study Group

1 reference

12 December 2020

Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group

1 reference

12 December 2020

Cost analysis of imipenem-cilastatin versus clindamycin with tobramycin in the treatment of acute intra-abdominal infection

1 reference

12 December 2020

Meta-analysis and quality of evidence in the economic evaluation of drug trials

1 reference

12 December 2020

Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections

1 reference

12 December 2020

Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery

1 reference

12 December 2020

Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial

1 reference

12 December 2020

Randomized comparative trial of imipenem/cilastatin versus aminoglycoside plus amoxycillin plus clindamycin in the treatment of severe intra- and post-operative infections

1 reference

12 December 2020

Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.

1 reference

12 December 2020

Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential

1 reference

12 December 2020

Management of secondary peritonitis

1 reference

12 December 2020

Meta-analysis. A useful tool for the spine researcher

1 reference

12 December 2020

Clinical use of β-lactamase inhibitors in combination with extended-spectrum penicillins

1 reference

12 December 2020

A prospective, randomized study of the comparative safety and efficacy of intraperitoneal imipenem versus vancomycin and netilmicin in the treatment of peritonitis on CAPD

1 reference

12 December 2020

Piperacillin/tazobactam: a critical review of the evolving clinical literature

1 reference

12 December 2020

Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group

1 reference

12 December 2020

Safety profile of piperacillin/tazobactam in phase I and III clinical studies

1 reference

12 December 2020

A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group

1 reference

12 December 2020

Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.

1 reference

12 December 2020

Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.

1 reference

12 December 2020

Peritonitis: update on pathophysiology, clinical manifestations, and management

1 reference

12 December 2020

A proposed classification of intra-abdominal infections. Stratification of etiology and risk for future therapeutic trials

1 reference

12 December 2020

Guidelines for clinical care: anti-infective agents for intra-abdominal infection. A Surgical Infection Society policy statement

1 reference

12 December 2020

Imipenem/cilastatin versus gentamicin/clindamycin: a cost effectiveness study

1 reference

12 December 2020

Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections

1 reference

12 December 2020

Comparative study of the cost-effectiveness of initial therapy with imipenem/cilastatin in secondary peritonitis

1 reference

12 December 2020

10.2165/00019053-200119010-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

24 November 2017

1028292582

0 references

1 reference